Connor, Clark & Lunn Investment Management Ltd. Altimmune, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Altimmune, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 40,705 shares of ALT stock, worth $335,816. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,705
Previous 18,517 119.83%
Holding current value
$335,816
Previous $123,000 102.44%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$5.5 - $8.1 $122,034 - $179,722
22,188 Added 119.83%
40,705 $249,000
Q2 2024

Aug 09, 2024
BUY
$5.91 - $10.23 $109,435 - $189,428
18,517 New
18,517 $123,000
Q3 2023

Nov 13, 2023
SELL
$2.4 - $3.45 $317,541 - $456,466
-132,309 Reduced 79.53%
34,052 $88,000
Q2 2023

Aug 10, 2023
BUY
$3.45 - $5.97 $302,923 - $524,189
87,804 Added 111.77%
166,361 $587,000
Q1 2023

May 09, 2023
BUY
$4.19 - $16.83 $329,153 - $1.32 Million
78,557 New
78,557 $331,000
Q3 2022

Nov 10, 2022
BUY
$10.67 - $22.41 $1.36 Million - $2.86 Million
127,562 New
127,562 $1.63 Million
Q4 2021

Feb 10, 2022
SELL
$8.69 - $12.48 $351,380 - $504,628
-40,435 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$8.43 - $16.81 $340,867 - $679,712
40,435 New
40,435 $457,000

Others Institutions Holding ALT

# of Institutions
186
Shares Held
39.3M
Call Options Held
913K
Put Options Held
743K
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email